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Abstract
Purpose: Thoracic reirradiation for non-small cell lung cancer with curative intent is potentially associated with severe toxicity. There
are limited prospective data on the best method to deliver this treatment. We sought to develop expert consensus guidance on the safe
practice of treating non-small cell lung cancer with radiation therapy in the setting of prior thoracic irradiation.
Methods and Materials: Twenty-one thoracic radiation oncologists were invited to participate in an international Delphi consensus
process. Guideline statements were developed and refined during 4 rounds on the definition of reirradiation, selection of appropriate
patients, pretreatment assessments, planning of radiation therapy, and cumulative dose constraints. Consensus was achieved once 75%
of respondents agreed with a statement. Statements that did not reach consensus in the initial survey rounds were revised based on
respondents’ comments and re-presented in subsequent rounds.
Results: Fifteen radiation oncologists participated in the 4 surveys between September 2019 and March 2020. The first 3 rounds had a
100% response rate, and the final round was completed by 93% of participants. Thirty-three out of 77 statements across all rounds
achieved consensus. Key recommendations are as follows: (1) appropriate patients should have a good performance status and can have
locally relapsed disease or second primary cancers, and there are no absolute lung function values that preclude reirradiation; (2) a full
diagnostic workup should be performed in patients with suspected local recurrence and; (3) any reirradiation should be delivered using
optimal image guidance and highly conformal techniques. In addition, consensus cumulative dose for the organs at risk in the thorax are
described.
Conclusions: These consensus statements provide practical guidance on appropriate patient selection for reirradiation, appropriate
radiation therapy techniques, and cumulative dose constraints.
 2021 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Curative-intent thoracic reirradiation is a second or
subsequent course of radiation therapy to the chest with
the goal of long-term disease control. Repeat irradiation
can be used in several different clinical scenarios: for
locally recurrent lung tumors, a metachronous lung tumor
distant from a previously irradiated lung tumor, a new
lung tumor arising in the previous radiation therapy field
of a different histologic tumor, or to metastatic disease
overlapping with a previous treatment. Each scenario will
have different underpinning tumor biology, outcomes,
and toxicities.
High-level evidence to guide practice of radical
thoracic reirradiation is lacking. The majority of the
studies of thoracic reirradiation are retrospective reports,
group different clinical situations together, and lack
consistent reirradiation doses or techniques. Given this
heterogeneity, the reported efficacy of high-dose re-
treatment strategies vary widely with a median overall
survival (OS) between 11.1 and 24 months.1
In the setting of non-small cell lung cancer (NSCLC),
local relapse occurs in a third of patients 2 years after
radical radiation therapy, and the rate of second primary
lung cancers at 10 years is 14%.2-4 We estimate 700 pa-
tients with NSCLC annually in the United Kingdom
would develop either a new primary or local recurrence
(based on UK audit data), for whom reirradiation may be
a treatment option.5 The number of patients being treated
with reirradiation is increasing.6 This is due to several
factors. The improved use of computed tomography (CT)
already results in increased detection of new primary tu-
mors. Relapsed disease will become more commonly
diagnosed as recent follow-up recommendations after
radical radiation therapy for NSCLC recommend frequentsurveillance CT scans.7 Furthermore, current radiation
therapy technology allows greater normal tissue sparing,
thus making reirradiation feasible. Nevertheless, reirra-
diation is a complex and potentially harmful treatment,
with a 5.2% to 23% risk of grade 3 pneumonitis and grade
5 toxicity rate up to 20% depending on technique and
tumor location.8
No formal guidelines exist on the selection of appro-
priate patients for curative-intent reirradiation or on rele-
vant cumulative dose constraints and planning/treatment
techniques. In addition, there is a lack of contemporary
clinical studies, with the last prospective trial of thoracic
reirradiation published in 2003.9 As reirradiation is
becoming more common, there is a need to share current
practice, identify areas of uncertainty, and develop
ongoing research questions. An international Delphi pro-
cess was therefore conducted to develop consensus
statements on the definition of reirradiation, patient
eligibility, radiation therapy planning technique, and cu-
mulative dose constraints. The scope of the statements
was limited to NSCLC because this is the most common
tumor for which curative-intent reirradiation is considered.
Methods and Materials
Participant selection
Thoracic radiation oncologists who have published
articles about reirradiation were contacted by e-mail to
participate in a series of questionnaires regarding their
reirradiation practice. If they were unable to participate in
the survey, they were able to nominate another radiation
oncologist familiar with lung reirradiation to participate.
We invited 21 clinicians from North America, Europe,
Asia, and Australia to take part in this process.
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Ethics approval was waived by the University of
Glasgow Ethics Committee and the West of Scotland
Research Ethics Committee. All participants consented to
the Delphi process.Questionnaires
The Delphi consensus method was selected as an un-
biased approach to obtain anonymized responses over a
wide geographic distance.10 Questionnaires were created
using a survey website (webprolol.com). Four rounds of
questionnaires took place. Consensus was deemed to be
reached once 75% of respondents strongly agreed or
agreed with a statement. Statements that did not reach
consensus in the initial survey rounds were revised by the
study organizers (RR/SH) based on respondents’ com-
ments and presented in subsequent rounds. The study
organizers did not take part in any of the surveys.
The first round captured the clinicians’ reirradiation
practice using mostly open-ended questions. The survey
was divided into 6 sections (a total of 36 questions):
definition of reirradiation, patient selection and pretreat-
ment assessment, reirradiation planning techniques, cu-
mulative dose constraints, expected toxicity of treatment,
and follow-up after reirradiation (Appendix 1, p 1-49).
The study organizers reviewed all of the responses,
identified common themes, and produced a series of
statements based on these answers. Where questions
involved numerical values (e.g., minimum lung function
test values for reirradiation), the median value of the an-
swers was used in the subsequent statement.
The second round featured 57 statements (Appendix 1,
p 50-126), and respondents rated each statement using a
5-point Likert scale (strongly agree, agree, neutral,
disagree, strongly disagree). For each statement, there was
a free text box for the participants to explain why they
agreed or disagreed with a statement and provide links to
further information (e.g. pertinent publications).
The comments and additional evidence suggested from
round 2 were used to refine the statements that did not
reach consensus. The third round consisted of 19 modified
statements to be rated using the Likert scale, again with
opportunity to comment on them (Appendix 1, p 127-
166). The questions relating to expected toxicity of
treatment were removed after round 2 because partici-
pants commented that reirradiation is a highly individu-
alized treatment and the expected toxicity may vary
depending on many factors, and therefore it would be
impossible to provide general guidance regarding this.
The fourth round was a single question on the defini-
tion of thoracic reirradiation (Appendix 1, p 167-170).
Two different definitions of reirradiation were presented
and clinicians were asked to choose one, both, or neither.The results of the previous 2 rounds were provided with
justification to illustrate how the definition was amended.
Reporting
The results are presented in 5 sections, with corre-
sponding tables describing the statements and level of
agreement. We also describe statements that did not reach
consensus; they are areas of controversy where further
research may be required. For items without consensus,
the statement with the highest degree of agreement from
any round is included in the results.
Results
Fifteen of 21 radiation oncologists from 7 countries
agreed to participate in this study. Countries represented
were the United Kingdom (3), United States (3), Australia
(3), Canada (2), the Netherlands (2), Switzerland (1), and
Singapore (1). The 15 participants have a total lung ra-
diation therapy experience of 222 years (median of 12
years each; range, 7- 34 years) and have authored 44 ar-
ticles about reirradiation or related topics. Additional
details are found in Appendix 2. The first round opened
on September 23, 2019, and the final survey was on
March 2, 2020. Rounds 1 to 3 had a 100% response rate,
and the final round had a response rate of 14 of 15
(93.3%).
Fifty-seven statements were created after the first
round of the Delphi process, and consensus was reached
in 26 statements (45.6%). After the second round, 14
statements were removed regarding expected toxicity of
treatment because the toxicity rates would depend on each
individualized treatment plan; therefore, it would be
impossible to form generalized statements. The third
round consisted of 19 statements, 7 of which reached
consensus (36.8%). Two additional statements were
added in the third round to clarify the need for biopsy in
reirradiation. The final round was one question on the
definition of reirradiation, and consensus was not reached.
This process is summarized in Figure 1. A table of all the
statements for which consensus was achieved and the
highest level of agreement statements where consensus
was not reached is presented in Appendix 3.
Definition of reirradiation
Despite 3 survey rounds to define reirradiation in
NSCLC, consensus was not achieved. The highest amount
of support was for the following round 2 definition: “any
dose of radical radiation for lung cancer, after initial radical
radiotherapy to the thorax or surrounding tissues for any
tumor histology, provided there is any overlap of previous
dose in either the planning target volume (PTV) or the
organs-at-risk (OARs)” (67% agreed). The respondents’
Figure 1 Schema of the consensus building process.
4 R. Rulach et al Advances in Radiation Oncology: MarcheApril 2021reasons for why they disagreed with this definition were
focused on the definition of overlap of OARs or PTV.
“Any overlap” would include low-dose regions, which may
be large and have little contribution to toxicity. In addition,
if 1 lesion were in the lung apex and a second lesion in the
lung base, there might be no dosimetric overlap at all, but a
significant volume of lung would be treated. Sixty percent
of respondents disagreed with setting an overlap isodose
level that would be considered significant (e.g., various
articles have used the 50% isodose level) because there are
no data to support it.
A suggested solution to this issue was to consider a
treatment to be reirradiation (as opposed to a second ra-
diation therapy to the lungs with no overlap) only if the
cumulative dose to either the OARs or PTV would exceed
the normal tissue dose constraints/prescribed dose to the
PTV that would be allowed for a single course of radia-
tion therapy with no correction for recovery. This option
was presented in round 3 but only achieved 60%
consensus. The lack of support for this definition centered
on the issue that overlap was important for toxicity in
serial organs within the thorax. However, overlap inparallel organs would be less significant because the total
volume of the organ irradiated may be of greater signifi-
cance. The round 3 definition would not account for
toxicity to parallel organs. Defining a volumetric
constraint (e.g. lifetime maximum irradiated volume of
lung) would be challenging due to the lack of data and the
likely significant variability among patients.
An alternative suggestion was to divide reirradiation
into 2 categories: (1) type I reirradiation for the local
relapse of NSCLC (ie, “salvage reirradiation”), with
likely a high degree of OAR dose overlap in serial or-
gans, and (2) type II reirradiation for a new primary
NSCLC, with little or no overlap between the 2 courses
of radiation therapy but an increased volume of lung
irradiated. Two versions of this concept were voted on in
the fourth round of the survey. In addition, 71.4% of
respondents were in favor of dividing reirradiation into
treatment of local relapse and new primary cancers but
could not converge on how to limit the definition to the
proximity of the original PTV. In addition, the 2 cate-
gories described would not account for the reirradiation
of metastases.
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Statements regarding patient selection and pretreat-
ment assessments that reached consensus are presented in
Table 1. There was agreement that reirradiation could be
considered in new primary NSCLC, local relapse (pro-
vided no central overlap), and nodal recurrence (in a
previously untreated area). Central overlap is defined as
the tumor being within 2 cm of the trachea, bronchi, or
proximal bronchial tree or the PTV abutting the medias-
tinal pleura or pericardium as per the Radiation Therapy
Oncology Group (RTOG) 0236 trial.11
Systemic treatment should be considered in metastatic
patients. Patients should have an Eastern Cooperative
Oncology Group performance status of 0 to 2 (with some
exceptions), no interstitial lung disease, and be staged
with computed tomography (CT) of the chest, whole body
positron emission tomography-CT (PET-CT), and mag-
netic resonance imaging (MRI) or CT of the head. Min-
imum pulmonary function test (PFT) values for
conventionally fractionated reirradiation could not be
agreed on in the second round, with consensus being
reached on using an individualized assessment of the
potential risks and benefits rather than using threshold
values, which have sparse supporting evidence.
A minimum interval between initial treatment and
reirradiation was investigated in the second and third
rounds, but consensus was not met. Twenty percent of
participants did not support any minimum time interval
between courses of radiation. However, most clinicians
agreed with a minimum of 6 months (73.3%), and a mi-
nority would not reirradiate unless the interval was greater
than 12 months (6.7%).
The survey section about expected risks of toxicity was
removed because the respondents felt unable to fully
answer the questions without patient input. Although not
a consensus statement, several respondents noted that
reirradiation is often a highly individualized treatment,
and understanding each patient’s acceptance of the risk of
side effects (including death), weighed against the
possible benefits of reirradiation or alternative therapies,
is crucial before embarking on treatment.Planning and delivery of reirradiation
Statements that reached consensus on radiation therapy
planning are shown in Table 2. There was agreement that
highly conformal treatments should be used for reirra-
diation, with preference for SABR when the reirradiation
target is small with minimal overlap with previously
treated OARs. In the event that an OAR dose constraint
would be exceeded due to being in the reirradiation PTV,
there was agreement that meeting the OAR dose
constraint should take priority. The minimum expansion
from gross tumor volume to clinical target volume did notreach consensus, with 66.7% agreeing to a minimum
expansion of 5 mm.
Cumulative dose constraints
Table 3 summarizes the agreed cumulative dose con-
straints for OARs in the thorax, based on several
studies.12-16 On the basis of comments from the first
round, to allow addition of different dose and fraction-
ations, dose constraints were expressed as a total equi-
effective dose in 2 Gy/fraction (EQD2) with no
adjustment for potential recovery.
No consensus was reached on the dose constraint for
the proximal bronchial tree. Suggested values for a
desired Dmax EQD2 of <80 Gy with an absolute
maximum dose of 105 Gy (a/b Z 3) reached 66.7%
agreement, based on 2 references.15,17
Follow-up after radiation therapy
In patients who are fit for further treatment after radical
reirradiation, surveillance CT is recommended every 3 to
6 months for the first 2 years and every 6 to 12 months
thereafter (86% consensus).Discussion
Summary of results
These statements from an international collaboration of
thoracic radiation oncologists provide consensus-based
recommendations for curative-intent thoracic reirradia-
tion. This information on patient selection, staging, cu-
mulative dose constraints, and radiation therapy
techniques can be used to aid clinicians’ decision making
and reduce toxicity from treatment.
Definition of reirradiation
Thoracic reirradiation may be suitable for a very het-
erogeneous patient group, and the selection of appropriate
patients is highly individualized. Therefore, the develop-
ment of a single definition for all thoracic reirradiation
was difficult. The problems encountered in this Delphi
process stemmed from the lack of data on how much
overlap would be significant in serial OARs, whether
large-volume low-dose reirradiation of the lungs has a
significant effect, and how to account for metastatic dis-
ease. A majority of clinicians (71.4%) agreed with
dividing NSCLC local relapse and new primaries into
different entities, but there remains a lack of robust evi-
dence to suggest that efficacy or toxicity is different in
either group.
Table 1 Consensus statements regarding suitable patients and pretreatment assessment
Consensus agreed SA/A, % N, % D/SD, % Round agreed Median
1.1 Radical reirradiation can be considered
for suspected new lung primaries with minimal
overlap with previous radiation therapy fields.
93 7 0 R2 SA
1.2 Radical reirradiation can be considered for lung
tumors that develop new nodal disease
after an initial course of radiation therapy only
to the primary tumor (therefore
minimal overlap).
100 0 0 R2 SA
1.3 Radical reirradiation can be considered where a
lung tumor relapses locally (or develops
a suspected second primary tumor with >50%
overlap with the original primary tumor),
but low overlap with serial structures in the
thorax.
93 0 7 R2 SA
1.4 Alternative treatments (e.g., systemic therapy) are
preferred to radical reirradiation to the
primary lung cancer where the lung tumors
have relapsed both locally and with
widespread metastatic disease.
93 7 0 R2 A
1.5 In general, patients should have an ECOG PS of
0-2 to be considered for radical dose
reirradiation, with exceptions being made for
selected PS 3 patients (e.g., SABR
reirradiation, or PS 3 due to nonrespiratory
issues).
93 0 7 R2 SA
1.6 Reirradiation should be avoided in patients with
interstitial lung disease.
86 7 7 R2 SA
1.7 Reirradiation should be performed cautiously with
patients who developed grade 3 or
higher toxicity with their initial radiation
treatment.
86 7 7 R2 A
1.8 Surgery should be considered in all appropriate
patients being assessed for reirradiation.
93 0 7 R2 A
1.9 In locally advanced recurrent lung cancer, where
there is an increased likelihood of
response to immunotherapy (e.g., PD-L1
>50%), immunotherapy may be preferable to
high-risk radical reirradiation.
80 0 20 R2 A
1.10 In locally advanced recurrent lung cancer, where
there is an actionable mutation (e.g.,
EGFR mutation, ALK fusion), targeted
treatment may be preferable to high-risk
radical reirradiation.
79 7 14 R2 A
1.11 Investigations before commencing radical
reirradiation are whole body PET-CT, CT
chest þ contrast, and CT/MRI brain.
>93 - - R2 Essential
1.12 Consideration for biopsy must be made in a tumor
board/multidisciplinary team meeting
before considering radical reirradiation.
86.6 6.7 6.7 R3 SA
1.13 Reirradiation can be considered where the tumor
board/multidisciplinary team agrees that
there is a high likelihood of cancer, but despite
best efforts, histologic confirmation of
cancer is not possible.
86.6 6.7 6.7 R3 SA
1.14 For conventionally fractionated reirradiation, the
clinician must consider re-treatment to
86.6 6.7 6.7 R3 A
(continued on next page)
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Table 1 (continued )
Consensus agreed SA/A, % N, % D/SD, % Round agreed Median
have a positive risk/benefit ratio considering the
current pulmonary function tests and
the likely exposure of the lung to reirradiation,
with no minimum PFTs values applicable.
1.15 For reirradiation with SABR, no minimum PFTs
apply.
87 0 13 R2 A
Abbreviations: ALK Z anaplastic lymphoma kinase; CT Z computed tomography; D/SD Z disagree/strongly disagree; ECOG Z Eastern
Cooperative Oncology Group; EGFR Z epidermal growth factor receptor; MRI Z magnetic resonance imaging; N Z neutral; PET-CT Z positron
emission computed tomography; PFT Z pulmonary function test; PD-L1 Z programmed death-ligand 1; PS Z performance status; R2 Z round 2;
R3 Z round 3; SA/A Z strongly agree/agree.
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Minimum PFT values for conventionally fractionated
radiation therapy and the need for a tumor biopsy required
further clarification after the second round. PFTs provide
an objective measure of respiratory reserve. However, the
panel did not agree on minimum values for forced expi-
ratory volume in 1 second or diffusing capacity. Several
of the panel commented on a threshold diffusing capacity
and forced expiratory volume in 1 second of 30% to 40%.
However, setting an absolute value was thought to be
unwise because other variables, such as the change in
lung function from the first to the second irradiation and
the site and volume of disease, also need to be considered.
The need for obtaining a biopsy was agreed in the third
round as important to consider. If the biopsy was not
possible, reirradiation could still be given with agreement
of the tumor board. This is a pragmatic approach because
often in areas that have been irradiated, the risks of biopsy
may be higher and what tissue is retrieved may be
nondiagnostic.
One area that was not fully considered in the surveys
was how to account for the efficacy and toxicity of the
initial radiation therapy. Patients are unlikely to derive
benefit from a second course of radiation if they progress
shortly after their first. This is supported by retrospective
data that show the longer the interval between treatments,
the longer the OS after reirradiation.18 The interval be-
tween treatments may describe tumor behavior, with
slower-growing tumors potentially after a less aggressive
clinical course. In addition, longer intervals allow for
more normal tissue recovery, reducing the risk of high-
grade toxicity. The majority of our group suggest a
minimum interval of 6 months. If grade 3 or above
toxicity occurred in the initial radiation therapy, then
reirradiation may cause more severe side effects. This
effect is seen in rat reirradiation models but unproven in
clinical practice.19 We suggest that reirradiation be used
cautiously considered in this instance.
The panel of thoracic radiation oncologists agreed that
it is appropriate to treat targets that were not previouslyirradiated (nodal relapse, second primary NSCLC), as
well as areas of local recurrence within previously irra-
diated areas. Local recurrence was considered to represent
radioresistant disease, which may be less responsive to re-
treatment. However, reirradiation may also be useful in
this instance to delay need for systemic treatment or
prevent serious local complications. In addition, reirra-
diation could be delivered in a way to overcome radio-
resistance (e.g. using high doses per fraction as in SABR).
Reirradiation using SABR has a promising local control
rate (1-year local control of 65%-95%), with a grade 3
pneumonitis rate of 2% to 30%.20 A review of using
SABR as a salvage treatment after radical radiation ther-
apy described a 2-year OS of 37% to 79% with acceptable
toxicities, suggesting this approach may be reasonable.21Planning and delivery of reirradiation
Reirradiation was considered using conventional frac-
tionation, intermediate hypofractionation, and ablative
dose schedules. SABR was recommended in non-ultra-
central, small-volume disease. Ultra-central is defined as
when the PTV overlaps either the main bronchi or tra-
chea.22 The potential benefits of SABR in reirradiation
have already been described. Additionally, the highly
conformal dose distributions and steep gradients associ-
ated with SABR reduce the cumulative dose to OARs
compared with conventionally fractionated treatments.
Tumor location when considering reirradiation is impor-
tant. The use of both SABR or conventionally fraction-
ated reirradiation for central local relapse is high risk.23-25
As the use of SABR has evolved, it is recognized that
ultra-central lesions are more likely to have serious side
effects than central disease, with a grade 5 toxicity rate of
up to 21%.22,26 Therefore, reirradiation using SABR for
ultra-central disease is not recommended. Provided the
tumor volume is suitable and that OARs can be avoided,
SABR may be appropriate for moderately central disease
(ie, centrally located, but not ultra-central). For peripheral
reirradiation, SABR is preferred.
Table 2 Consensus statements regarding radiation therapy planning technique
Consensus agreed SA/A, % N, % D/SD, % Round agreed Median
2.1 When combining initial and
reirradiation plans, either rigid or
deformable dose registration are
acceptable methods (although there
are considerable uncertainties in
either process, and additional
investigation is warranted).
80 6 14 R2 SA
2.2 18-FDG-PET/CT is recommended to
aid tumor volume delineation.
86 7 7 R2 SA
2.3 When contouring for conventionally
fractionated radical reirradiation, an
acceptable minimum expansion from
CTV to PTV is 5 mm (or follow
institutional guidelines where
available).
86 7 7 R2 A
2.4 PTV coverage can be compromised to
achieve acceptable OAR doses.
80 6 14 R2 SA
2.5 Radical reirradiation should be
performed using highly conformal
radiation therapy techniques (e.g.,
VMAT, tomotherapy, CyberKnife).
100 0 0 R3 SA
2.6 SABR is the preferred reirradiation
technique where the tumor is not
ultracentral, the tumor volume is
small, and there is minimal overlap
with OARs.
80 13.3 6.7 R2 SA
2.7 Protons may have a role for reirradiation
and requires further evaluation in the
context of a clinical trial.
80 20 0 R3 A
2.8 Acceptable doses for conventionally
fractionated radical thoracic
reirradiation are 60 Gy in 30 fractions
or 55 Gy in 20 fractions once daily
for non-small cell lung cancer.
93 0 7 R2 A
2.9 Daily cone beam CT is recommended
for treatment verification for
conventionally fractionated
reirradiation.
100 0 0 R2 SA
2.10 Any dose and fractionation that can
safely deliver a BED >100 Gy to the
tumor is acceptable for radical
reirradiation with SABR.
86.7 0 13.3 R3 A
2.11 Daily cone beam CT is recommended
for treatment verification for SABR
reirradiation.
100 0 0 R2 SA
Abbreviations: BED Z biologically effective dose; CT Z computed tomography; CTV Z clinical target volume; D/SD Z disagree/strongly
disagree; N Z neutral; OAR Z organ at risk; PTV Z planning target volume; R2 Z round 2; R3Z round 3; SA/A Z strongly agree/agree; VMAT
Z volumetric arc therapy; 18-FDG-PET/CT Z 18-fluorodeoxyglucose positron emission tomography/computed tomography.
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lative OAR dose. A planning study comparing reirra-
diation with intensity modulated proton therapy and
volumetric arc therapy suggested that intensity modu-
lated proton therapy was associated with a statistically
significant reduction in dose to the spinal cord, lungs,and heart and a trend for reduced dose in the other
thoracic OARs.27 Two prospective registry studies of
proton reirradiation reported a grade 3 toxicity rate
between 7% and 42% and a grade 5 toxicity rate of 3.8%
to 10.5%.28,29 Our group suggested investigating this
further with a clinical trial.
Table 3 Consensus statements regarding cumulative dose constraints
Consensus agreed SA/A, % N, % D/SD, % Round agreed Median
3.1 There is insufficient evidence to suggest
volumetric cumulative dose
constraints for the lung due to the
changes in anatomy and function of
the lung after an initial course of
radiation therapy.
80 13.3 6.7 R3 A
3.2 For radical reirradiation, the desirable
cumulative maximum point dose
constraint to the esophagus is an
EQD2 of 75 Gy, although up to 100
Gy is acceptable (using an a/b Z 3);
the volume of the esophagus getting
55 GY should be less than 35%
(V55Gy <35%).12
86 7 7 R2 A
3.3 For radical reirradiation, the desirable
cumulative maximum point dose
constraint to the spinal cord is an
EQD2 of 60 Gy (using a/b Z 2),
with a maximum EQD2 of 67.5 Gy
(provided that the initial irradiation
dose to the cord did not exceed 50
Gy).13
80 13 7 R2 A
3.4 For radical reirradiation, the desirable
cumulative maximum dose (Dmax)
constraint to the brachial plexus is an
EQD2 of 80Gy (a/b Z 2) and an
acceptable cumulative Dmax is 95 Gy
(if the interval between treatments is
>2 years).14
80 0 20 R2 A
3.5 For radical reirradiation, the desirable
cumulative maximum dose (Dmax)
constraint to the aorta is an EQD2 of
115 Gy (a/b Z 3). The desirable
cumulative Dmax to the pulmonary
artery is an EQD2 of 110 Gy.15,16
80 0 20 R2 A
3.6 There is a lack of information to guide
reirradiation dose constraints for the
skin and the heart, therefore the use of
other guidelines (e.g., QUANTEC or
SABR guidelines) and to keep the
dose to these organs as low as
reasonably achievable are
recommended.
100 0 0 R2 A
Abbreviations: D/SD Z disagree/strongly disagree; EQD2 Z equieffective dose in 2 Gy/fraction; N Z neutral; QUANTEC Z quantitative analyses
of normal tissue effects in the clinic; R2 Z round 2; R3 Z round 3; SA/A Z strongly agree/agree.
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Cumulative dose constraints are crucial for the safe
practice of reirradiation. These have been difficult to
establish due to the lack of both preclinical evidence
about normal tissue recovery and dose/toxicity data.
Radiobiologically, a degree of normal tissue recovery
takes place after the first course of radiation therapy, but
there is no data in humans as to how much tolerance isregained. Recent publications from Paradis et al, Troost
et al, and the American Radium Society suggest cumu-
lative reirradiation OAR dose constraints and are
summarized in Table 4.6,27,30
In this study, cumulative lung reirradiation dose con-
straints were not agreed on, with respondents citing lack
of evidence for traditional V5Gy and V20Gy limits in this
setting. An alternate approach for reirradiation dose con-
straints for parallel OARs is to use a critical volume-dose
Table 4 A comparison of putative cumulative dose constraints
OAR a/b This study (EQD2) Paradis et al (EQD2)*




Spinal cord 2 Dmax 60 Gy D0.1cc <56.25 Gy Dmax <65 Gy Dmax <57 Gy
Esophagus 3 Dmax 75-100 Gy D0.1cc <90.6 Gy Dmax <100 Gy V60 <40%, Dmax <100-110 Gy
Brachial plexus 2 Dmax 80-95 Gy D0.1cc <85 Gy Dmax <85 Gy Dmax <85 Gy
Great vessels 3 Dmax 110 e 115 Gy D0.1cc <123 Gy Dmax <110 Gy Dmax <120 Gy
PBT 3 Dmax <80-105 Gy
z D0.1cc <90.6 Gy Dmax <110 Gy Dmax <110 Gy
Skin/Chest wall 2.5 ALARA D0.1cc <105 Gy n/a n/a
Heart 2.5 ALARA D0.1cc <85 Gy Dmean <70 Gy V40<50%
Lung 3 Individualized Individualized Dmean <22 Gy V20<40%
Abbreviations: ALARAZ as low as reasonably achievable; EQD2Z equieffective dose in 2 Gy fractions; OAR Z organs at risk; PBT Z proximal
bronchial tree.
* Dose constraints converted from a/b ratio of 2.5 to the stated a/b ratios in the table to allow ease of comparison; dose constraints derived using a
6- to 12-month interval, with OARs being treated to tolerance in the first treatment.
y Dose constraints a/b ratios not quoted in the American Radium Society abstract.
z Consensus not reached.
10 R. Rulach et al Advances in Radiation Oncology: MarcheApril 2021(CV) constraint.31 This approach has been used in the
RTOG 0915 and 0813 trials for lung SABR to ensure a
given volume of lung receives less than a threshold
dose.32,33 For example, the RTOG 0813 protocol man-
dates that 1500 cm3 of lung should receive less than 12.5
Gy. The principle underlying this constraint is to preserve
a minimum volume of functional lung. This was not
suggested by the respondents but may be a useful
approach in the reirradiation setting and could be adopted
in future reirradiation trial designs.
There is a pressing need for prospective data collection
of cumulative OAR doses and associated toxicity to refine
these estimates. There will be inaccuracies in this process
(e.g., registration of dose to OARs from the initial radi-
ation therapy to the reirradiation plan, actual dose deliv-
ered to the OAR may be different from the initial plan due
to differences in position). Despite this, it will provide
some initial validation of the suggested constraints.Strengths and limitations
This Delphi consensus process uses international
expert opinion to generate contemporary thoracic reirra-
diation recommendations. The paucity of prospective
trials in this area and the wide range of clinical scenarios
that reirradiation can be considered for limits the strength
of the recommendations that can be made. The selection
process of participants initially focused on whether they
had publications on reirradiation. This excludes unpub-
lished clinicians with extensive clinical experience of
reirradiation. In addition, as it would be impractical to
invite all authors with articles related to reirradiation, an
inherent limitation of this study is that the participants are
a selected group of clinicians. Therefore, it is likely there
will be alternate opinions on the statements presented
here. Nevertheless, as reirradiation is a nonstandardtreatment, guidance in how to identify suitable patients
and perform safe reirradiation is useful.
Conclusions
The key recommendations of this consensus are that a
full diagnostic workup should be performed in patients
with suspected local recurrence; curative intent treatment
such as radical reirradiation or surgery should be
considered for localized recurrence; any reirradiation
should be delivered using optimal image guidance and
highly conformal techniques; and prospective registries
and clinical trial data are urgently needed.
Supplementary Materials
Supplementary material for this article can be found at
https://doi.org/10.1016/j.adro.2021.100653.
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